Posted by Michael Wonder on 28 May 2019
ICER’s assessment highlights the risk-benefit tradeoffs of investigational treatments for peanut allergy
28 May 2019 - To achieve commonly cited thresholds for cost-effectiveness, the annual price would need to be between $4,800-$7,200 for AR101 and $3,000-$4,500 for Viaskin Peanut; the CTAF will vote on the net benefit of treatments during 11 June public meeting.
The ICER today released an Evidence Report assessing the comparative clinical effectiveness and value of two investigational technologies that treat children with peanut allergy by building their immune tolerance to peanuts.
The report evaluates Viaskin Peanut (DBV Technologies), AR101 (Aimmune Therapeutics), and non-commercialised oral immunotherapy. An FDA decision on AR101 is expected by January 2020. A biologics license application for Viaskin Peanut was withdrawn in December 2018, but is expected to be resubmitted later this year.
